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Abstract 
Background: Acute hyperglycemia is associated with worse outcomes in diabetic patients admitted with ST‑eleva‑
tion myocardial infarction (STEMI). However, the impact of full‑scale decompensated diabetes on STEMI outcomes has 
not been investigated.
Methods: We utilized the national inpatient sample (2003–2014) to identify adult diabetic patients admitted with 
STEMI. We defined decompensated diabetes as the presence of diabetic ketoacidosis (DKA) or hyperglycemic hyper‑
osmolar state (HHS). We compared in‑hospital morbidity and mortality and cost between patients with and without 
diabetes decompensation before and after propensity‑score matching.
Results: A total of 73,722 diabetic patients admitted with STEMI were included in the study. Of those, 1131 (1.5%) suf‑
fered DKA or HSS during the hospitalization. After propensity‑score matching, DKA/HHS remained associated with a 
significant 32% increase in in‑hospital mortality (25.6% vs. 19.4%, p = 0.001). The DKA/HHS group also had higher inci‑
dences of acute kidney injury (39.4% vs. 18.9%, p < 0.001), sepsis (7.3% vs. 4.9%, p = 0.022), blood transfusion (11.3% 
vs. 8.2%) and a non‑significant trend towards higher incidence of stroke (3.8% vs. 2.4%, p = 0.087). Also, DKA/HHS 
diagnosis was associated with lower rates of referral to coronary angiography (51.5% vs. 55.5%, p = 0.023), coronary 
stenting (26.1% vs. 34.8%, p < 0.001), or bypass grafting (6.2% vs. 8.7%, p = 0.033). Referral for invasive angiography was 
associated with lower odds of death during the hospitalization (adjusted OR 0.66, 95%CI 0.44‑0.98, p = 0.039).
Conclusions: Decompensated diabetes complicates ~ 1.5% of STEMI admissions in diabetic patients. It is associated 
with lower rates of referral for angiography and revascularization, and a negative differential impact on in‑hospital 
morbidity and mortality and cost.
Keywords: Myocardial infarction, Diabetic ketoacidosis, Hyperosmolar hyperglycemic state, Coronary angiography, 
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Background
The impact of acute hyperglycemia on clinical out-
comes of diabetic and non-diabetic patients admitted 
with ST-elevation myocardial infarction (STEMI) has 
been extensively studied. High admission blood glucose 
among STEMI patients is associated with higher short-
term incidences of failed reperfusion, acute kidney injury, 
stent thrombosis, myocardial damage and death among 
[1–12]. In addition, hyperglycemia during STEMI hospi-
talizations in diabetics predicted left ventricular remod-
eling and survival during long-term follow-up [13–18]. 
However, large-scale outcomes data of STEMI patients 
with acutely decompensated diabetes manifesting as dia-
betic ketoacidosis (DKA) or hyperglycemic hyperosmo-
lar state (HHS) are scarce [11]. We utilized a nationwide 
representative sample to assess the contemporary trends 
in the incidence and in-hospital morbidity and mortality 
and cost of decompensated diabetes (defined as DKA or 
HSS) among diabetic patients admitted with STEMI.
Methods
Study data
The National Inpatient Sample (NIS) was used to derive 
patient relevant information between January, 1st 2003 
and December, 31st 2014. The NIS is the largest publicly 
available all-payer administrative claims-based database 
and contains information about patient discharges from 
approximately 1000 non-federal hospitals in 45 states. It 
contains clinical and resource utilization information on 
5–8 million discharges annually, with safeguards to pro-
tect the privacy of individual patients, physicians, and 
hospitals. These data are stratified to represent approxi-
mately 20% of US inpatient hospitalizations across dif-
ferent hospital and geographic regions (random sample). 
National estimates of the entire US hospitalized popula-
tion were calculated using the Agency for Healthcare 
Research and Quality sampling and weighting method.
Study population
Patients > 18-year-old with a principle discharge diag-
nosis of ST-elevation myocardial infarction (Interna-
tional Classification of Diseases-Ninth Revision-Clinical 
Modification [ICD-9-CM] codes 410.×1 except 410.71) 
between 2003 and 2014 were identified in the NIS. Non-
diabetic patients were then excluded yielding a cohort of 
diabetic patients admitted with STEMI. Those were then 
stratified into patients with or without decompensated 
diabetes. Similar to prior studies, we defined decom-
pensated diabetes was defined as: diabetes with ketoaci-
dosis (ICD-9-CM codes 250.10-250.13) or diabetes 
with hyperosmolaity (ICD-9-CM codes 250.20-250.23) 
[19, 20]. Myocardial infarction codes used in this study 
have a negative predictive value of 96.1%, and a positive 
predictive value of 95.9% and are similar to what has been 
reported in other studies [21, 22].
Outcomes analysis and study endpoints
A comparative analysis was performed between diabetic 
patients admitted with STEMI with and without DKA/
HSS before and after propensity score matching for the 
primary end point of in-hospital mortality, and for the 
secondary end points of in-hospital complications, length 
of stay, post-discharge intermediate care utilization and 
cost.
To account for potential confounding factors and 
reduce the effect of selection bias, a propensity score-
matching model was developed using logistic regression 
to derive two matched groups for the comparative out-
comes analysis. Patients admitted with STEMI with or 
without DKA/HHS were entered into a nearest neighbor 
1:1 variable ratio, parallel, balanced propensity-match-
ing model using a caliper of 0.01 without replacement 
to ensure perfect matching. Variables included in the 
propensity match model are listed in Additional file  1: 
Table S1.
We anticipated that decompensated diabetes will have 
a differential impact on referral patterns for invasive 
angiography. We hence examined the impact of inva-
sive angiography referral on in-hospital mortality among 
patients with decompensated diabetes using a multivari-
able logistical regression analysis model.
Statistical analysis
Descriptive statistics presented as frequencies with per-
centages for categorical variables and as means with 
standard deviations for continuous variables. Base-
line characteristics were compared using a Pearson Chi 
squared test and Fisher’s exact test for categorical vari-
ables and an independent-samples t test for continuous 
variables. Matched categorical variables were presented 
as frequencies with percentages and compared using 
McNamar’s test. Matched continuous variables were pre-
sented as means with standard deviations and compared 
using a paired-samples t-test. A type I error rate of < 0.05 
was considered statistically significant. To assess mono-
tonic trends of utilization and outcomes we employed the 
non-parametric Mann-Kendal trend method. All statisti-
cal analyses were performed using SPSS version 24 (IBM 
Corporation, Armonk, NY) and R, version 3.3.1.
Results
A total of 73,722 diabetic patients (weighted national 
estimate = 362, 362) admitted with STEMI between Janu-
ary 1st, 2003 and December 31st, 2014 were included 
in the study. Of those, 72,591 patients (98.5%) had com-
pensated diabetes and 1131 (1.5%) suffered DKA or HSS 
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during the hospitalization with modest temporal increase 
in this incidence during the study period (Fig. 1). Patients 
with DKA/HHS were younger (63 ± 15 vs. 67 ± 15 years, 
p < 0.001) and a distinctive risk profile compared with 
diabetic patients without DKA/HHS, characterized with 
lower incidences of hypertension, hyperlipidemia, smok-
ing, chronic obstructive lung disease, known coronary 
artery disease, and prior atrial fibrillation (Table 1).
Patients with decompensated diabetes had higher inci-
dences of cardiogenic shock (23.9% vs. 9.3%), and cardiac 
arrest (11.8% vs. 5.6%), and were less likely to undergo 
coronary angiography (51.4% vs. 61.1%), percutaneous 
coronary intervention (PCI) (25.8% vs. 40%), or coronary 
bypass grafting (6.2% vs. 9.2%) (P < 0.001 for all) (Tables 1, 
2). However, referral to coronary angiography and PCI 
increased overtime (Fig. 2).
Outcomes of the unmatched cohorts
Compared with patients with decompensated diabetes, 
those with DKA/HHS had over twofold higher in-hos-
pital mortality (26.4% vs. 11.9%, p < 0.001) and higher 
incidences of acute kidney injury (40% vs. 13.3%), stroke 
(3.7% vs. 1.6%), sepsis (7.5% vs. 1.9%), blood transfu-
sion (11.3% vs. 8.2%) and mechanical ventilation (8.6% 
vs. 2.9%), (p < 0.001 for all). They also had longer hospi-
talizations (7 ± 8 vs. 5 ± 6  days, p < 0.001), higher hos-
pital charges (87,382 ± 132,119$ vs. 64,396 ± 81,185$, 
p < 0.001), and were less likely to be discharged directly to 
home (58.7% vs. 68.4%, p < 0.001) (Table 3).
Outcomes of the matched cohorts
Following propensity-score matching, baseline character-
istics between the two sets of STEMI patients with and 
without DKA/HHS became well matched (Additional 
file  1: Table  2 and Figure S1). The presence of DKA/
HHS remained associated with significantly lower rates 
of referral to coronary angiography (52.2% vs. 57.1%, 
p = 0.023), and PCI (29.5% vs. 38.4%, p < 0.001) (Addi-
tional file  1: Table  S3). In these propensity-matched 
cohorts, DKA/HHS remained associated with a sig-
nificant 32% increase in in-hospital mortality (25.6% vs. 
19.4%, p = 0.001). The DKA/HHS group also had signifi-
cantly higher incidences of acute kidney injury (39.4% vs. 
18.9%, p < 0.001), sepsis (7.3% vs. 4.9%, p = 0.022), and a 
non-significant trend towards higher stroke (3.8% vs. 
2.4%, p = 0.087). Similar to the unmatched cohorts, they 
also had longer hospitalizations, higher hospital charges 
and were less likely to be discharged directly to home 
(Table 3).
Given that patients in the decompensated diabetes 
group were less likely to be referred for invasive angiog-
raphy and they also had higher in-hospital mortality, the 
impact of invasive angiography referral on in-hospital 
mortality among these patients was examined using a 
multivariable logistical regression analysis model. This 
model adjusted for demographics, baseline clinical risk 
factors, insurance status and hospital characteristic, and 
showed that referral for invasive angiography was associ-
ated with lower odds of death during the hospitalization 
Fig. 1 Trends in the incidence of decompensated diabetes among diabetic patients admitted with STEMI
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(adjusted OR 0.66, 95%CI 0.44–0.98, p = 0.039). Variables 
included in this regression models are the same variables 
used for propensity score matching outlined in Addi-
tional file 1: Table S1.
Discussion
The main findings of the present investigation are: (1) 
acute diabetes decompensation occur in 1.5% of diabetics 
admitted with STEMI, (2) those patients have less preva-
lence of previously diagnosed coronary artery disease, 
but higher incidences of cardiogenic shock and cardiac 
arrest, (3) patients with decompensated diabetes were 
less likely to undergo coronary angiography and revas-
cularization compared with patients with compensated 
diabetes, (4) referral to angiography was independently 
associated with lower risk-adjusted odds of in-hospital 
Table 1 Baseline characteristics of the study’s population
SD standard deviation
Baseline characteristics Compensated diabetes N = 72,591 
NE = 356,810
Decompensated diabetes N = 1113 
NE = 5553
P value
Age‑mean (SD), years 64 ± 14 63 ± 15 < 0.001
Female 41.0% 47.3% < 0.001
Race 0.752
 Caucasian 70.5% 70.1%
 African American 10.5% 11.5%
 Hispanic 11.1% 11.2%
Dyslipidemia 52.3% 32.4% < 0.001
Hypertension 70.8% 51.7% < 0.001
Prior sternotomy 7.3% 6.5% 0.361
Chronic lung disease 18.2% 13.7% < 0.001
Atrial fibrillation/flutter 15.5% 12.0% 0.001
Anemia 16.1% 19.4% 0.003
Coagulopathy 4.0% 7.5% < 0.001
Conduction abnormality 5.8% 7.2% 0.05
Congestive heart failure 0.7% 4.7% < 0.001
Cardiogenic shock 9.3% 23.9% < 0.001
Drug abuse 1.4% 3.3% < 0.001
Smoking 26.6% 20.6% < 0.001
Vascular disease 10.4% 8.8% 0.077
Coronary artery disease 64.6% 48.4% < 0.001
Prior stroke 3.3% 2.6% 0.182
Chronic renal failure 17.4% 21.2% 0.001
Liver disease 1.1% 2.0% 0.005
Teaching hospital 43.2% 44.8% 0.285
Rural hospital location 15.1% 12.5% 0.016
Primary payer‑no (%) < 0.001
Medicare/medicaid 65.1% 62.0%
Private insurance 25.3% 24.8%
Self‑pay 6.0% 9.8%
No charge/other 3.7% 3.4%
Table 2 Management patterns in the unmatched cohorts
PTCA percutaneous transluminal coronary angiography, IV intravenous, PCI 
percutaneous coronary intervention, BMS bare metal stent, DES drug eluting 
stent
Management Compensated 
diabetes 
N = 72,591 
NE = 356,810 
(%)
Decompensated 
diabetes
 N = 1113 
NE = 5553 (%)
P  value
Coronary angiography 62.9 52.3 < 0.001
Coronary intervention 43.2 29.6 < 0.001
 IV thrombolysis 1.8 1.3 0.218
 Underwent PTCA 3.2 3.7 0.308
 Underwent PCI 40.0 25.8 < 0.001
  BMS 27.4 15.4 < 0.001
  DES 13.4 10.8 < 0.001
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death in patients with decompensated diabetes, and (5) 
acute diabetes decompensation was associated with 32% 
higher in-hospital mortality, higher incidences of certain 
key morbidities, more resource utilization, and higher 
cost.
Prior studies have shown that the hyperglycemia dur-
ing STEMI admissions is not uncommon in both diabet-
ics and non-diabetics, and hyperglycemia in this setting 
is associated with worse short and long-term outcomes 
[1–18]. Nonetheless, to our knowledge, the incidence of 
full-scale uncontrolled hyperglycemia (decompensated 
diabetes) manifesting as DKA or HHS and its impact on 
clinical outcomes among STEMI patients have not been 
previously investigated.
Our analysis reveals that the incidence of DKA or 
HHS among diabetic patients admitted with STEMI is 
low (1.5%) but is associated with lower odds of under-
going revascularization, and higher morbidity and 
mortality and cost. Albeit intuitive, the findings of our 
study deserve more scrutiny:
1. The lower prevalence of known coronary artery dis-
ease and the worse initial presentation (evident by 
Fig. 2 Trends in percutaneous coronary revascularization among diabetic patients admitted with STEMI
Table 3 In-hospital outcomes of STEMI patients with and without DKA/HHS
UTI urinary tract infection, IC intermediate care facility, SD standard deviation, LOS length of stay
Clinical outcome Unmatched cohorts Matched cohorts
Compensated 
diabetes
N = 72,591 
NE = 356,810 
(%)
Decompensated diabetes 
N = 1113 NE = 5553 (%)
P
value
Compensated diabetes 
N = 1103 NE = 5410 (%)
Decompensated diabetes 
N = 1103 NE = 5410 (%)
P  value
Death 11.9 26.4 < 0.001 19.4 25.6 0.001
Blood transfusion 8.2 11.3 < 0.001 11.7 11.1 0.689
Acute kidney injury 13.3 40.0 < 0.001 18.9 39.4 < 0.001
New dialysis 0.4 0.5 0.521 0.5 0.5 0.99
Stroke 1.6 3.7 < 0.001 2.4 3.8 0.087
UTI 7.4 13.1 < 0.001 8.3 13.1 0.001
Sepsis 1.9 7.5 < 0.001 4.9 7.3 0.022
Acquired pneumonia 6.6 12.0 < 0.001 7.5 12.1 < 0.001
Mechanical ventilation 2.9 8.6 < 0.001 7.1 8.0 0.456
Tracheostomy 0.6 1.5 <0.001 2.6 1.0 0.006
Discharged home 60.3 43.3 < 0.001 51.0 44.1 0.01 
Discharged to IC 26.9 29.1 28.3 29.2
LOS (mean ± SD) 5 ± 6 7 ± 8 < 0.001 6 ± 7 7 ± 7 0.02
Total charges ($) 64,396 ± 81,185 87,382 ± 132,119 < 0.001 76,983 ± 109,872 84,527 ± 125,828 0.133
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the higher incidence of cardiogenic shock and car-
diac arrest) in the DKA/HHS population are absorb-
ing. Although speculative, these patients may have 
constituted a different cohort of patients at baseline 
that is characterized with worse chronic glycemic 
control, attenuated symptoms due to diabetic neu-
ropathy, delayed presentations, and possibly larger 
infarcts [23, 24].
2. The interrelation between DKA/HHS and worse out-
comes in STEMI patients is rather complex and may 
be difficult to unravel from cohort analyses like the 
present one. Several studies have shown than uncon-
trolled hyperglycemia is associated with high plasma 
catecholamine levels, oxidative stress, and endothe-
lial and microvascular dysfunction possibly leading 
to higher incidence of no reflow, larger infarcts and 
hence worse STEMI outcomes [1, 25, 26]. Vice versa, 
the occurrence of DKA/HHS during a STEMI admis-
sion may be related to worse STEMI profile in these 
patients (cardiogenic shock or cardiac arrest). These 
patients may experience more intense hemody-
namic and hormonal derangements and hence may 
develop DKA or HHS as a result for their ‘higher-
risk’ STEMI. Further studies are needed to deline-
ate the impact of variable degrees of hyperglycemia 
on STEMI outcomes and to identify the associated 
underlying mechanisms.
3. Patients with DKA/HHS were less likely to be 
referred to angiography, although this has improved 
with time. Reasons for this ‘less invasive’ practice are 
not known and can not be ascertained in our study. 
Nonetheless, referral for angiography was indepen-
dently associated with improved in hospital survival 
suggesting a potential opportunity for improvement 
in this cohort.
4. The excess associated mortality of DKA/HHS was 
significantly attenuated after rigorous propensity 
score matching: 26.4% vs. 11.9%, p < 0.001 before 
matching, and 25.6% vs. 19.4%, p = 0.001 after match-
ing. This suggests that baseline and hospital charac-
teristics played a key role in the variance of outcomes 
between the two groups.
Limitations
Our study has a number of limitations. (1) The NIS is an 
administrative database that gathers data for billing pur-
poses and can be limited by erroneous coding. Neverthe-
less, the Healthcare Cost and Utilization Project’s quality 
control minimizes the discrepancies related to diagnosis 
coding. Also, both the procedures and the hard clinical 
endpoints reported in our study are hard to miscode. (2) 
Angiographic data, and information on peri-procedural 
hemodynamics, medications use, are not available in the 
NIS. (3) Similarly, granular data on blood glucose levels, 
and insulin use as well as the timing of the DKA/HHS 
diagnoses are not captured in NIS. (5) Pre-admission 
diabetic control and anti-diabetic medications are not 
included in this dataset. Several studies have suggested 
a possible impact of Metformin and other anti-diabetics 
on infarct size and outcomes in diabetic patients admit-
ted with STEMI [27–29]. This potential effect can not be 
assessed with the current study design. (4) Significant dif-
ferences in baseline risk profiles were noted between the 
two groups. The impact of unmeasured confounders on 
the comparative analysis cannot be ruled out. Nonethe-
less, we believe that our rigorous propensity score match-
ing should minimize that risk.
Conclusions
Decompensated diabetes complicates ~ 1.5% of STEMI 
admissions in diabetic patients. It is associated with lower 
rates of referral for angiography and revascularization, 
and a negative differential impact on in-hospital morbid-
ity and mortality and cost. Further studies are needed to 
identify preventative and management strategies to miti-
gate the excess morbidity and mortality in these patients.
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